Mesoblast (ASX:MSB) onboarded ten transplant centers in the US for the supply of Ryoncil for the treatment of steroid-refractory acute graft versus host disease during the March quarter, and the firm plans to recruit ten more priority transplant centers during the June quarter, according to a Wednesday Australian bourse filing.
The firm brought on board a team of nine key account managers in the last week of April, who will focus on onboarding the remaining 35 priority transplant centers, accounting for 80% of US pediatric transplants.
It also secured a Type B meeting with the US Food and Drug Administration scheduled for the June quarter to discuss the accelerated approval pathway for Revascor, a candidate for the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.
Its shares fell 2% in recent trading on Wednesday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。